A randomized, placebo‐controlled, dose‐escalation phase I/II multicenter trial of low‐dose cidofovir for BK polyomavirus nephropathy
Hannah Imlay(University of Utah), Ajit P. Limaye(University of Washington), Richard J. Whitley(University of Alabama at Birmingham), Deborah Adey(University of California, San Francisco), Milagros Samaniego(Henry Ford Health System), Jo‐Anne H. Young(University of Minnesota System), Alexander C. Wiseman, James Rooney(Gilead Sciences (United States)), V. Ram Peddi(University of Maryland, Baltimore), Michelle A. Josephson(University of Chicago), John W. Gnann(Birmingham VA Medical Center), Clifton E. Kew(University of Alabama)
Cited by 5
Related Papers
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
|American Journal of Kidney Diseases|2015|1.3k
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
|The Lancet Infectious Diseases|2021|450
Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study
|Clinical Infectious Diseases|2020|407